Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone in Refractory Neuromyelitis Optica
NCT02021825Phase 4Unknown
- Sponsor
- Xuanwu Hospital
- Start
- Mar 2009
- Primary completion
- Dec 2014
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in neuromyelitis optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Xuanwu Hospital. Primary endpoints: Annual Relapse Rate at 1 year and Expanded Disability Status Scale at 6 months. Status: unknown.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
neuromyelitis optica (NMO)Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT02021825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02021825.